IPC flags adverse reactions linked to levetiracetam and nasal decongestants

The Indian Pharmacopoeia Commission has identified suspected links between levetiracetam and gingival hypertrophy, and between xylometazoline or oxymetazoline and rebound nasal congestion. Healthcare professionals and patients are advised to monitor for these adverse reactions and report suspected cases to the Pharmacovigilance Programme of India through its prescribed reporting channels.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.